Back to today’s briefing

Story perspectives

Indivior Halts Opvee Marketing Amid FDA Struggles

10/2/2025

37 3

Summary

Story summary

Indivior PLC halted Opvee marketing after FDA approval in 2023 failed to gain traction.
The New York State Attorney General settlement requires Indivior to stop making false Opvee claims.
Opvee will continue being manufactured but requires a prescription; naloxone is available over-the-counter (OTC).
Indivior may divest Opvee to focus on Sublocade; 2024 Opvee revenue was $15 million.

1 of 1

Story summary

Indivior PLC halted Opvee marketing after FDA approval in 2023 failed to gain traction.
The New York State Attorney General settlement requires Indivior to stop making false Opvee claims.
Opvee will continue being manufactured but requires a prescription; naloxone is available over-the-counter (OTC).
Indivior may divest Opvee to focus on Sublocade; 2024 Opvee revenue was $15 million.